32 Biosciences to Launch $40 Million Series A at J.P. Morgan to Advance First-in-Class GI Mucosal-Immune Therapeutics
Microbiome-focused company receives $6 million in funding to advance gut health platform technologies.
32 Biosciences Set to Attend the 2026 JPM Healthcare Conference
Microbiome-focused company receives $6 million in funding to advance gut health platform technologies.
32 Biosciences Joins Featured Startups in the Midwest Biotech Startup Showcase
Microbiome-focused company receives $6 million in funding to advance gut health platform technologies.
32 Biosciences receives $6 million in funding to advance gut microbiome platform technologies
32 Biosciences announced it has received $6 million in funding to support the continued development of its lead assets. The funding comes as the company prepares for a future Series A fundraise and advances toward key regulatory milestones.
32 Biosciences Raises $6M, Advances Gut Microbiome Diagnostics Toward FDA Clearance
Chicago-based biotech exceeds fundraising goals while building leadership team for regulatory milestones
Chicago startup 32 Biosciences raises $6 million, eyes FDA approval next
A Chicago-based biotech startup is making waves in the gut health industry, securing millions in funding to advance its innovative microbiome tools.
32 Biosciences Surpasses Financing Target, Accelerates Toward Series A and FDA Milestones
Microbiome-focused company receives $6 million in funding to advance gut health platform technologies.